Novus Biologicals enhances HIF product line by launching new antibody

Novus Biologicals, a leading supplier of hypoxia-inducible factor (HIF) antibodies, launched a new mouse monoclonal HIF Prolyl Hydroxylase 3 antibody this week (catalog number NBP1-30440).  This antibody, clone EG188e/d5, is made to the partial recombinant human PHD3 protein (UniProt accession number Q9H6Z9).  It cross-reacts with bovine, human,  monkey, mouse and rat, and is useful for Western blot analysis and immunohistochemistry on paraffin-embedded sections.  NBP1-30440 was QC tested on Cobalt chloride treated COS-7 nuclear extracts producing a band at ~27kDa, which can be viewed here.

This clone EG188e/d5 has been cited in three scientific publications, including:

  • Appelhoff RJ, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004 Sep 10;279(37):38458-65. [PMID: 15247232]
  • Stolze IP et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes.  J Biol Chem. 2004 Oct 8;279(41):42719-25. [PMID: 15302861]
  • Soilleux EJ et al. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology. 2005 Dec;47(6):602-10. [PMID: 16324198]

Novus Biologicals also provides a line of over 1,700 antibodies related to hypoxia research, many of which are HIF target genes complimenting this new HIF Prolyl Hydroxylase 3 antibody.


For more information on this new antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Wednesday, March 24, 2010 - 06:00